Nordion is a global health science company that provides medical isotopes and sterilization technologies. It has approximately 450 employees serving over 500 customers in more than 40 countries. Nordion is focused on optimizing its medical isotopes business and maintaining its sterilization business. It is also committed to environmental, health and safety standards. Nordion's talented employees work to maintain a global leadership position and build shareholder value.

1. www.nordion.com
NORDION
Corporate Presentation
September 5, 2013

2. 2
Caution on Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of applicable securities laws, including under
applicable Canadian securities laws and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act
of 1995. These statements can be identified by expressions of belief, expectation or intention, as well as those statements that are
not historical fact. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”
and similar words and expressions are also intended to identify forward-looking statements. Forward-looking statements are
necessarily based on estimates and assumptions made by us in light of our experience and our perception of historical trends,
current conditions and expected future developments, as well as other factors that we believe are appropriate in the
circumstances, but which are inherently subject to significant business, political, economic and competitive uncertainties and
contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-
looking statements. Accordingly, this presentation is subject to the disclaimer and qualified by the assumptions, qualifications and
risk factors referred to in our 2012 Annual Information Form (AIF).
We caution readers not to place undue reliance on the Company’s forward-looking statements, as a number of factors could
cause our actual results, performance or achievements to differ materially from any forward-looking statements. We do not
assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to
time by us or on our behalf, except as required by applicable law.

3. 3
About Nordion
Delivering quality products to our global
customers for more than 60 years, our product
portfolio includes:
• Sterilization Technologies
• Medical Isotopes
Nordion is a health science company that
provides market-leading products used for
the prevention, diagnosis and treatment of
disease.

4. 4
A Global Company
APPROXIMATELY
450 EMPLOYEES
SUPPLY OVER
500 CUSTOMERS
AROUND
30 PRODUCTS
ACROSS MORE THAN
40 COUNTRIES
68%
UNITED STATES
18%
ROW
10%
EUROPE
4%
CANADA
F2012 REVENUES BY REGION - $244.8M*
*Revenues and regional breakdown include Targeted Therapies business, which was divested in July 2013 to BTG plc.

5. 5
103.6 108.7 95.4
89.4
122.8
101.0
29.0
42.6
48.5
0
50
100
150
200
250
300
2010 2011 2012
2012 Financial Highlights
Revenue Trend (US$ Millions)
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
** Key supplier down for repairs for 10 months in F2010
Medical Isotopes** Targeted Therapies*Sterilization Technologies

6. 6
47.5 46.1
39
13.4
38.3
29.4
9.1
12.7
14.1
0
20
40
60
80
100
120
2010 2011 2012
2012 Financial Highlights
Segment Earnings Trend (US$ Millions)
Medical Isotopes** Targeted Therapies*Sterilization Technologies
Excludes corporate segmented loss
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
** Key supplier down for repairs for 10 months in F2010

7. 7
Q3 2013 Results
32.1
36.5
22.0
24.0
13.0
11.1
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
2012 2013
Q3 Q3
Segmented Revenue
(US$ millions)
Segmented Earnings*
(US$ millions)
14.4
17.8
4.6
5.94.3
0.5
0
5
10
15
20
25
30
2012 2013
* Excludes corporate segmented loss
** In July 2013, Nordion divested its Targeted Therapies business to BTG plc
Medical Isotopes Targeted Therapies**Sterilization Technologies

8. 8
F2013 Timeline
DEC 4
Provided
update on
arbitration-
related costs
by AECL
JAN 26
Filed amended
statement of
claim against
AECL
JAN 28
Appointed
Grant Gardiner
as
SVP, General
Counsel
MAY 23
Entered into
agreement to
divest Targeted
Therapies business
to BTG
JUL 15
Announced
divestiture
completion of
Targeted Therapies
business to BTG
MAR 21
Settled claims
with
Dr. Reddy's
Labs
MAY 15
Signed contract
manufacturing
agreement with
Navidea
AUG 20
Reach settlement
with AECL to
resolve MAPLE
lawsuits and
arbitration costs
Update – remove Sept 5

9. 9
Leading Products in Global Markets
POTENTIAL >
< PRIORITY >
STERILIZATION
TECHNOLOGIES
TARGETED
THERAPIES
ADVANTAGE >
Optimize Medical Isotopes
business
• Pursue long-term supply
• Maintain customer
relationships
• Transition business to BTG
plc
• Maintain quality customer
service and supplier
relationships
Maintain Sterilization
business; selectively invest
in growth:
• Geographic expansion
• New applications
• Global leader in cobalt-60
• Significant barriers to entry
• Solid cash flow and gross
margins
• Recurring revenue base
• A global provider in
processing, packaging, &
delivery
• Extensive regulatory
expertise and logistics &
distribution network
Approximately 40% of single-
use medical products
worldwide are sterilized using
gamma sterilization
technologies
Over 10,000 hospitals
worldwide use radioisotopes
in medical procedures with
about 90% being for
diagnosis.
MEDICAL
ISOTOPES
DIVESTED BUSINESS GO-FORWARD BUSINESSES

10. 10
Specialty Isotopes: Sterilization Technologies
• Gamma sterilization is focused on
the prevention of disease
• Co-60 is used to sterilize medical devices,
instruments and supplies and food
• Customers of Co-60 include
contract sterilization service providers
and medical device and product manufacturers
• The Nordion Gamma Centre of Excellence is a
world class applied research and specialty gamma
processing facility to promote and expand the use
of gamma globally
• Nordion manufactures Co-60 irradiation sources,
and designs, constructs and maintains commercial
gamma sterilization systems

11. 11
MARKET MIX PRODUCTS DRIVERS
80%
10%
• Stents
• Patches
• Tissue
• Regen medicine
+ Aging population
+ Enhance devices
+ Leverage drugs
+ Stem cell research
10%
Sterilization Market Segmentation
MEDICAL & SURGICAL
BIO-ACTIVE DEVICES
FOOD SAFETY
• Syringes
• Catheters
• Drapes, gowns
• Sutures, gloves
+ Aging population
+ Min invasive surgery
+ Smaller devices
+ Material
• Fruits & vegetables
• Spices
• Meat and poultry
• Ready To Eat (RTE)
+ FDA labeling
+ USDA FEA
+ Food safety concerns
10%
80%

12. 12
Specialty Isotopes: Medical Isotopes
• Medical isotopes are used to prevent, diagnose
and treat disease
• Main isotope supply sources
are nuclear reactors and cyclotrons
• Primary product is Mo-99, which decays for use in
Technetium-99 (Tc-99m) generators, used in
imaging to diagnose heart disease and cancers
• Other Key Reactor Isotopes:
– Xenon-133 (Xe-133), used in lung scans;
– Iodine-131 (I-131), used to treat hyperthyroidism, thyroid
cancer and non-Hodgkin’s lymphoma;
– Iodine-125 (I-125), used to treat prostate cancer;
• Key Cyclotron Isotopes:
– Iodine-123 (I-123), used to diagnose thyroid disease;
– Strontium-82 (Sr-82), used to manufacture rubidium-82
generators, which are used in imaging to diagnose heart
disease
– Thallium-201 (Tl-201), used to diagnose and assess risk of
coronary artery heart disease;
– Palladium-103 (Pd-103), used to treat prostate cancer;
– Indium-111 (In-111) and Gallium-67 (Ga-67) (both used to
diagnose infection and cancer) at our Vancouver facilities

13. 13
Medical Isotopes (Mo-99) Supply Chain
• Established, reliable facilities providing high-quality isotopes to global customers
• Specialty skills in operations, regulatory affairs and global logistics
Irradiation of
HEU targets to
produce crude
isotopes
NUCLEAR
REACTORS
Purification of
Mo-99 and
distribution to global
radiopharmaceutical
manufacturers
MEDICAL ISOTOPE
PROCESSORS
Tc-99m
Generator
manufacturing
and distribution to
radiopharmacies
RADIOPHARMACEUTICAL
MANUFACTURERS
Unit dose
compounding and
distribution to
hospital/departments
RADIOPHARMACIES
AND HOSPITALS
Critical physiological
diagnosis enabling
informed therapeutic
decisions
PHYSICIANS
AND PATIENTS

14. 14
Nordion Environmental, Health,
and Safety (EH&S) Program
• Creating a workplace that enriches
the health and well-being of Nordion
employees
• Demonstrating Environmental, Health,
and Safety (EH&S) regulatory excellence
• Improving EH&S performance –
continually
• Managing EH&S with excellence

15. 15
Nordion Environmental, Health,
and Safety (EH&S) Program
• Implementing measures in the design and operation of all of
our facilities to keep radiation dose received by workers and
the public ALARA (as low as reasonably achievable)
• Implementing an ISO 14001-based environmental
management (EMS) system at our Ottawa site
• Establishing EH&S objectives and targets annually
to continually improve our performance
• Maintaining - and building on - a comprehensive training
program for employees and contractors
• Engraining EH&S excellence into the Nordion culture
• Investing in a world class approach to EH&S
ISO 14001: 2004 certified
Recipient of the Government of Canada 2007 ENERGY STAR ® Market Transformation Award
Practitioner of LeanSigma, a methodology used to continually improve processes
Recipient of an unprecedented ten-year license renewal from the Canadian Nuclear Safety Commission (CNSC)

16. 16
In the Community
Other Programs:
• Employee Giving Program - Nordion
makes donations to not-for-profit
organizations nominated by employees
• Proud sponsor of the Gala for Research,
an annual black-tie event to support
the Ottawa Hospital Research Institute,
the research arm of The Ottawa Hospital
• Sponsor and key supporter of the
University of Ottawa Heart Institute
Telethon
Ride the Rideau
Title sponsor of Ride the Rideau since its inauguration in 2010, Nordion has helped to
raise over $4.4 million for cancer research at The Ottawa Hospital Research Institute.

17. 17
The talented, dedicated and
resilient people that make
up Nordion share a single
purpose:
• Maintain a global leadership
position in our key markets
• Build value for shareholders
through the execution of our
strategic priorities
• Be a trusted, world-class provider
of healthcare products to our
customers
Business Outlook

18. www.nordion.com
Find out more at
www.nordion.com
Follow us at
http://twitter.com/NordionInc